Cancer, a multifaceted disease, continues to challenge the global healthcare
landscape, with colon cancer being a prominent contributor to its burden. Colon cancer,
also known as colorectal cancer (CRC), arises from the colon or rectum and ranks
among the most prevalent malignancies worldwide. Its emergence can be attributed to a
complex interplay of genetic, environmental, and lifestyle factors. Despite
advancements in diagnostics and treatment modalities, the incidence of CRC has
witnessed a concerning rise in recent years, prompting an urgent need for innovative
therapeutic strategies. Surgical resection remains the primary curative option for
localized disease, while systemic treatments are employed for advanced stages.
Biomarkers, pivotal in elucidating CRC pathogenesis and progression, play a crucial
role in guiding therapeutic interventions and prognostication. Molecular biomarkers
like microsatellite instability (MSI) and mutations in genes like KRAS, BRAF, and
TP53 serve as prognostic indicators and guide treatment selection. Understanding the
intricate signaling pathways involved in CRC development has led to the exploration of
novel therapeutic targets. Targeting key signaling pathways, such as the Wnt/β-catenin
pathway, PI3K/Akt/mTOR pathway, and the MAPK pathway, has shown potential in
preclinical studies and clinical trials, offering avenues for innovative treatment
modalities. Overall, the evolving landscape of CRC demands a multidisciplinary
approach integrating advanced diagnostics, targeted therapies, and personalized
medicine. Biomarkers, with their pivotal role in elucidating molecular pathways and
guiding treatment decisions, stand as a beacon of hope in the pursuit of more effective
and tailored therapeutic interventions for colorectal cancer.
Keywords: Biomarkers, Cancer, Colorectal cancer (CRC), Liquid biopsies, Molecular profiling, Ppersonalized medicine, Signaling pathways, Therapeutic strategies, Targeted therapy, Wnt/β-catenin pathway.
